Do we eradicate Helicobacter pylori in hospitalized patients with peptic ulcer disease?

被引:7
作者
Wong, Frank [1 ]
Ou, George [1 ]
Svarta, Sigrid [1 ]
Kwok, Ricky [1 ]
Donaldson, Kieran [1 ]
Frenette, Joe [1 ]
Enns, Robert [1 ]
机构
[1] St Pauls Hosp, Div Gastroenterol, Dept Med, Vancouver, BC V6Z 1Y6, Canada
来源
CANADIAN JOURNAL OF GASTROENTEROLOGY | 2013年 / 27卷 / 11期
关键词
Helicobacter pylori; Peptic ulcer disease; Upper GI bleeding; MEDICARE PATIENTS; DUODENAL-ULCER; INFECTION; PREVALENCE; METAANALYSIS; CURE;
D O I
10.1155/2013/249562
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
BACKGROUND: Helicobacter pylori infection is the most common chronic infection in humans. It is a major contributor to the cause of duodenal and gastric ulcers worldwide. Its eradication has been shown to reduce rates of H pylori-related ulcers as well as other complications such as gastric cancer. OBJECTIVE: To determine the rate of appropriate treatment in patients following a diagnosis of H pylori infection on biopsy during esophagoduodenoscopy for upper gastrointestinal bleeding over a four-year period at a tertiary centre in Vancouver, British Columbia. Also evaluated was the rate of eradication confirmation using the urea breath test. METHODS: A retrospective review of 1501 inpatients who underwent esophagoduodenoscopy for upper gastrointestinal bleeding (January 2006 to December 2010) was undertaken. Patients who were biopsy stain positive for H pylori were selected for drug review either via a provincial database (PharmaNet) or via records from patients' family practitioners. Data were also obtained via two provincial laboratories that perform the urea breath test to determine the rates of confirmation of eradication. RESULTS: Ninety-eight patients had biopsy-proven H pylori. The mean (+/- SD) age was 56.13 +/- 17.9 years and 65 were male. Data were not available for 22 patients; the treatment rate was 52.6% (40 of 76). Of those treated, 12 patients underwent a post-treatment urea breath test for eradication confirmation. CONCLUSION: There was substantial discrepancy between the number of diagnosed H pylori infections and the rate of treatment as well as confirmation of eradication. Numerous approaches could be taken to improve treatment and eradication confirmation.
引用
收藏
页码:636 / 638
页数:3
相关论文
共 22 条
[1]
[Anonymous], 1994, INFECT HELICOBACTER, V61, P177
[2]
Archimandritis A, 1998, J INTERN MED, V243, P251
[3]
REGRESSION OF PRIMARY GASTRIC LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID-TISSUE TYPE AFTER CURE OF HELICOBACTER-PYLORI INFECTION [J].
BAYERDORFFER, E ;
NEUBAUER, A ;
RUDOLPH, B ;
THIEDE, C ;
LEHN, N ;
EIDT, S ;
STOLTE, M .
LANCET, 1995, 345 (8965) :1591-1594
[4]
The safety implications of missed test results for hospitalised patients: a systematic review [J].
Callen, Joanne ;
Georgiou, Andrew ;
Li, Julie ;
Westbrook, Johanna I. .
BMJ QUALITY & SAFETY, 2011, 20 (02) :194-199
[5]
American college of gastroenterology guideline on the management of Helicobacter pylori infection [J].
Chey, William D. ;
Wong, Benjamin C. Y. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 (08) :1808-1825
[6]
Accuracy of Helicobacter pylori diagnostic tests in patients with bleeding peptic ulcer:: A systematic review and meta-analysis [J].
Gisbert, JP ;
Abraira, V .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (04) :848-863
[7]
TREATMENT OF HELICOBACTER-PYLORI REDUCES THE RATE OF REBLEEDING IN PEPTIC-ULCER DISEASE [J].
GRAHAM, DY ;
HEPPS, KS ;
RAMIREZ, FC ;
LEW, GM ;
SAEED, ZA .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1993, 28 (11) :939-942
[8]
Screening for Helicobacter pylori and nonsteroidal anti-inflammatory drug use in medicare patients hospitalized with peptic ulcer disease [J].
Hood, HM ;
Wark, C ;
Burgess, PA ;
Nicewander, D ;
Scott, MW .
ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (02) :149-154
[9]
HELICOBACTER-PYLORI ERADICATION REDUCES THE RATE OF REBLEEDING IN ULCER HEMORRHAGE [J].
JASPERSEN, D ;
KOERNER, T ;
SCHORR, W ;
BRENNENSTUHL, M ;
RASCHKA, C ;
HAMMAR, CH .
GASTROINTESTINAL ENDOSCOPY, 1995, 41 (01) :5-7
[10]
KUIPERS EJ, 1995, ALIMENT PHARM THERAP, V9, P59